Sunshine Biopharma is trading at $2.97, up 8.35% in pre-market, with the cause of the November 4, 2026 rise unclear.
- No clear company-specific announcement or catalyst for the rise was identified.
- The latest company release found was the October 22 reverse stock split announcement, which predates the move.
- Market context is mixed and does not establish a broader-market explanation.